戻る
Annovis Bio Inc (ANVS) 収入
ANVS 株価推移チャート
ANVS 収入
Annovis Bio Inc
$2.28
7.54%
$0.15
終値： Apr 02, 16:00:00 GMT-4
$2.22
-2.63%
$-0.05
アフターマーケット：Apr 02, 20:00:00 GMT-4
主要データ
前終値
$2.12
始値
$2.06
当日レンジ
$2.03 - $2.29
52週レンジ
$1.11 - $5.5
取引高
962.5K
平均取引高
450.6K
配当利回り
--
1株当たり利益(TTM)
-1.39
時価総額
$62.9M
ANVSとは何ですか？
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.